CVS Health Corporation research snapshot
CVS AI stock analysis currently reads CVS Health as a recovering integrated health care platform with pharmacy retail, Caremark PBM, Aetna insurance, and care delivery assets. At the August 2, 2026 data cutoff, CVS traded near $104.43, down from its July 2026 high near $110.68 but still up about 68% over the trailing 52 weeks, while Q1 2026 revenue grew 6.2% to $100.4 billion and management raised full-year 2026 adjusted EPS guidance to $7.30 to $7.50. On July 14, 2026, CVS Caremark reached a global settlement with the FTC that resolved its rebate, pharmacy network, and vertical integration litigation while adding operating commitments such as moving away from rebate guarantees and spread pricing. The CVS AI stock forecast is scenario-based, not a precise prediction, because the investment case depends on Aetna medical cost execution, how the FTC agreement changes PBM economics, pharmacy reimbursement pressure, care delivery discipline, debt reduction, and whether the market values CVS on recovered adjusted earnings or still-disrupted GAAP earnings.
Current price
$104.43
Market cap
$133.25 billion verified market cap
AI score
66 / 100
Rating
Improving health care turnaround with strong revenue scale, a resolved Caremark FTC settlement, high leverage, and policy-sensitive earnings risk
Trend status
Constructive but consolidating, above both the 50-day and 200-day moving averages after a pullback from the July high
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | CVS sells pharmacy access, prescription benefit management, health insurance, retail health services, and care coordination to members, employers, plans, and patients at national scale. | High |
| Moat | Scale, pharmacy density, Caremark claims data, Aetna membership, specialty pharmacy capabilities, employer relationships, and integrated benefit design create switching costs, but the July 2026 FTC settlement and ongoing policy pressure can narrow the moat by resetting PBM pricing structures. | Medium-high |
| Management | David Joyner is executing a margin recovery and simplification plan, raised full-year 2026 guidance in Q1, and settled the Caremark FTC litigation, with credibility improving but still tied to medical cost control, care delivery discipline, and smooth implementation of the FTC agreement terms. | Medium |
| Financial trend | FY2025 total revenues rose 7.85% to $402.1 billion and TTM revenue reached $405.6 billion, but FY2025 GAAP net income attributable to CVS Health fell to $1.77 billion after impairment and litigation charges, with TTM net income at $2.93 billion. | High |
| Valuation | At $104.43, CVS screens near 45.49x TTM EPS, 13.65x forward earnings, 1.72x book value, 18.02x free cash flow per share, and a 2.55% dividend yield, with a consensus price target of $112.19. | High |
| Technical trend | CVS is above the 50-day moving average near $101.11 and the 200-day average near $84.58, with RSI near 49.05 and the price consolidating below the 52-week high of $110.68. | Medium |
| Risk level | Main risks are elevated medical costs, Medicare Advantage margin pressure, the cost and revenue impact of the FTC settlement terms, pharmacy reimbursement pressure, debt, store footprint changes, care delivery execution, and political scrutiny. | Medium-high |
| AI confidence | Descriptive confidence is high because company filings and StockAnalysis data align on the major facts. Forecast confidence is lower because the FTC changes, medical cost trend, and policy headlines are hard to model. | High data confidence |
| Investment certainty | CVS has a credible turnaround and the FTC settlement removes a litigation overhang, but after the rally the setup needs continued guidance execution and visible margin of the new PBM model rather than just a low historical multiple story. | Medium |
CVS AI stock forecast
The CVS AI stock forecast uses the $104.43 price reference, TTM EPS of $2.30, management 2026 adjusted EPS guidance of $7.30 to $7.50, consensus 2026 adjusted EPS near $7.45, and a scenario model. The mechanical adjusted EPS model produced roughly $129 in a bullish case, $108 in a base case, and $79 in a bearish case under 16x, 14x, and 11x multiples, which lands inside the analyst target range of $79 to $148. The practical takeaway is that the forecast swings on whether adjusted EPS converts into durable cash earnings without new impairments, medical cost shocks, or margin damage from the Caremark FTC agreement.
$120 to $140
More likely if CVS delivers raised 2026 adjusted EPS guidance, Health Care Benefits margins keep recovering, the Caremark FTC changes are implemented without meaningful margin damage, cash flow stays above $9.5 billion, debt falls, and investors assign a mid-teens multiple to sustainable adjusted EPS.
$100 to $120
More likely if revenue grows in the low to mid single digits, adjusted EPS improves but GAAP earnings remain noisy, the PBM model reset costs a modest amount of economics, and the market prices CVS near its consensus target of $112.19 while waiting for cleaner Aetna and care delivery results.
$70 to $95
More likely if medical cost trend rises, the FTC-related changes plus PBM regulation reset economics more than modeled, pharmacy reimbursement pressure offsets volume, Oak Street or other care assets need more charges, or debt limits shareholder returns.
CVS AI technical analysis
CVS AI technical analysis is constructive but consolidating as of the August 2, 2026 cutoff. StockAnalysis showed a July 31, 2026 close of $104.43, a 50-day moving average near $101.11, a 200-day moving average near $84.58, RSI near 49.05, 20-day average volume near 7.49 million shares, and a 52-week range of $61.19 to $110.68. The stock pulled back from the July high, so momentum cooled from overbought to neutral while the price still holds above both moving averages.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $104.43 | StockAnalysis listed the July 31, 2026 close at $104.43, after a pullback from the 52-week high near $110.68. |
| Immediate support | $100 to $102 | This zone brackets the 50-day moving average near $101.11 and the first psychological support below the current price. |
| Moving-average support | $101 | The 50-day moving average near $101.11 is the first trend support to watch on any further pullback. |
| Major support | $84 to $85 | The 200-day moving average near $84.58 is the larger trend reference if the turnaround trade unwinds. |
| Near resistance | $106 to $111 | This range spans prior swing highs and the 52-week high near $110.68, and may require Q2 results to clear. |
| Upper resistance | $115 to $125 | This is a potential extension zone if Q2 results and 2026 guidance continue to improve and analysts raise targets further. |
| Moving averages | 50-day near $101.11, 200-day near $84.58 | Price is above both averages, so trend remains positive while CVS holds above the 50-day reference. |
| Momentum | RSI near 49.05 | Momentum cooled from overbought territory in July to a neutral reading, giving the pullback room before risk of another extension. |
| Volume | 20-day average near 7.49 million shares | Volume confirmation matters because Q2 earnings, medical cost commentary, and PBM policy headlines can reverse the move. |
| Volatility | Watch Aug. 5, 2026 earnings | Q2 results, medical benefit ratio commentary, FTC agreement execution updates, and guidance are likely volatility catalysts. |
| Invalidation | Close below $101, then below $84.58 | A sustained break below the 50-day average would weaken the short-term setup. A break below the 200-day average would challenge the broader recovery thesis. |
CVS AI trading strategy
The CVS AI trading strategy below is a rules-based research framework, not personal advice. It links the stock chart with Aetna margin recovery, Caremark PBM durability after the FTC settlement, pharmacy reimbursement pressure, cash flow, debt, dividends, and management guidance.
Watch for CVS to hold above the $101 to $102 50-day moving-average zone and break above $106 to $111 with Q2 results on August 5, 2026 confirming adjusted EPS guidance, medical cost discipline, and cash flow strength.
A failed breakout followed by a close below $101 should reduce trend confidence, especially if management points to higher medical costs, weaker PBM economics, or unexpected costs from the FTC agreement.
If CVS pulls back toward $90 to $101 without a cut to 2026 guidance or deterioration in operating cash flow, compare the lower price with the base-case recovery range and dividend coverage.
Do not treat a lower price as attractive if GAAP earnings remain impaired by new charges, the Caremark changes compress margins, debt reduction stalls, or Aetna margins fail to improve.
Track Health Care Benefits medical benefit ratio, Caremark client retention and pricing structure changes, pharmacy reimbursement pressure, Oak Street clinic decisions, adjusted EPS guidance, operating cash flow, debt, dividend coverage, and FTC agreement implementation milestones.
Position sizing should reflect that CVS is a regulated health care turnaround with an unusually policy-sensitive PBM segment, not a guaranteed defensive compounder.
Investment research summary
Customers pay CVS to make health care access, prescriptions, benefits, insurance, and care coordination more convenient and affordable. The company monetizes pharmacy traffic, prescription volume, PBM scale, insurance premiums, and care delivery relationships.
The moat comes from national retail pharmacy presence, Caremark scale, Aetna membership, claims data, specialty pharmacy, employer and plan relationships, and integrated benefit design. The moat is not absolute because the July 2026 FTC settlement and regulators can reset PBM economics and reimbursement terms.
The thesis fails if medical costs exceed pricing, Medicare Advantage margins stay weak, the FTC settlement terms or further PBM reform remove economics, pharmacy reimbursement pressure accelerates, care delivery assets require more charges, or debt limits strategic flexibility.
David Joyner is trying to rebuild credibility through margin recovery, cash flow discipline, store optimization, tighter care delivery decisions, and a negotiated end to the Caremark FTC fight. The proof point is whether improved adjusted earnings show up in cleaner GAAP earnings, stable PBM margins under the new model, and lower balance-sheet risk.
CVS sits inside a long-term U.S. health care affordability problem where payers, employers, pharmacies, and patients need lower friction and better coordination. That supports demand, but the same affordability pressure creates regulation, litigation, and pricing risk, and PBM scrutiny is now a permanent industry feature.
At $104.43, CVS trades near 13.65x forward earnings, 18.02x free cash flow, and a 2.55% dividend yield, with a consensus target of $112.19. Margin of safety depends on whether adjusted EPS near $7.30 to $7.50 becomes durable cash earnings and whether the FTC agreement, medical costs, and debt stop absorbing the recovery.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CVS quote reference | $104.43 close on July 31, 2026, within a 52-week range of $61.19 to $110.68 | StockAnalysis CVS overview | August 2, 2026 |
| Market capitalization verification | $133.25 billion reported and $133.67 billion calculated from $104.43 x 1.28 billion shares, a 0.32% deviation that passes the Pineify financial_rigor.py gate | Pineify financial_rigor.py and StockAnalysis CVS overview | August 2, 2026 |
| Shares outstanding | 1.28 billion shares outstanding, with shares up 1.07% over the trailing year | StockAnalysis CVS statistics | August 2, 2026 |
| FY2025 and TTM revenue | $402.1 billion FY2025 total revenues in the company release, cross-checked against StockAnalysis FY2025 revenue of $402.07 billion and TTM revenue of $405.62 billion | CVS Health FY2025 results release and StockAnalysis financials | August 2, 2026 |
| FY2025 and TTM net income | $1.77 billion net income attributable to CVS Health for FY2025, with StockAnalysis TTM net income at $2.93 billion due to newer trailing-period timing | CVS Health 2025 Annual Report and StockAnalysis statistics | August 2, 2026 |
| Q1 2026 results and guidance | $100.4 billion Q1 revenue, $2.30 GAAP EPS, $2.57 adjusted EPS, and raised 2026 adjusted EPS guidance of $7.30 to $7.50 with cash flow from operations guided to at least $9.5 billion | CVS Health Q1 2026 results release | August 2, 2026 |
| FTC Caremark settlement | Global settlement on July 14, 2026 resolved rebate, pharmacy network contracting, and vertical integration litigation, with commitments to move away from rebate guarantees and spread pricing, delink manufacturer compensation from list prices, and count TrumpRx purchases toward deductibles | CVS Health press release | August 2, 2026 |
| Cash and debt | $11.80 billion cash and cash equivalents and $78.35 billion total debt on the StockAnalysis current balance sheet, versus $10.60 billion cash and $79.95 billion debt at Dec. 31, 2025 | StockAnalysis CVS statistics and financials | August 2, 2026 |
| Valuation ratios | 45.49x TTM EPS, 13.65x forward earnings, 1.72x book value, 18.02x free cash flow per share, 2.55% dividend yield, and 33.49x EV/EBITDA | Pineify financial_rigor.py and StockAnalysis CVS statistics | August 2, 2026 |
| Analyst consensus and target | Buy consensus from 28 analysts with a $112.19 average price target, a $79 low, and a $148 high; recent raises include BofA to $120, UBS to $122, Truist to $118, and Wells Fargo to $123 | StockAnalysis CVS forecast | August 2, 2026 |
| Technical indicators | 50-day moving average $101.11, 200-day moving average $84.58, RSI 49.05, 20-day average volume 7.49 million, and 52-week range $61.19 to $110.68 | StockAnalysis CVS statistics | August 2, 2026 |
This CVS AI stock analysis is an informational research tool only and is not investment advice, tax advice, or a recommendation to buy or sell CVS Health Corporation shares. Forecast scenarios are based on available public data as of August 2, 2026 and can be wrong if earnings, medical costs, the FTC agreement outcomes, regulation, debt, interest rates, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
